Following Scuttled Mergers, Insurers Consider Next Steps
Both the Anthem-Cigna and Aetna-Humana megamergers have been blocked, so what is next for insurers? According to Bloomberg, the companies may consider other deals with the cash they have allocated. Plus, companies may try new deals with the hope that the Trump administration’s antitrust officials may be more open to large takeovers. Humana may still remain a sought after target for deals.
GOP Split on ACA Repeal Timeline
Some of the more conservative members of the Republican Party are calling for a faster repeal of the Affordable Care Act (ACA). They believe that President Donald Trump’s speculation that the repeal could happen next year, and even assertions from House Speaker Paul Ryan, R-Wisconsin, that repeal would happen by the end of this year, are too slow, reported Kaiser Health News. This subset of the party is pushing to repeal the ACA now even without a replacement ready—something insurers and other stakeholders, as well as some party leaders now, are opposed to.
Should You Finish Antibiotics?
The instruction from doctors that patients finish prescribed antibiotics even when they feel better may go away. STAT reported that such a directive might actually be exacerbating antibiotic resistance. Patients who take antibiotics when they are no longer sick may drive bacteria in the body to develop a resistance so the antibiotics don’t work the next time there is an infection. The World Health Organization will debate the argument in March.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More